The numbers of human immunodeficiency virus (HIV) infected peoples over the age of 50 have grown in the past decade as has changing disease biology for the nervous system. Indeed, HIV-associated neurocognitive disorders (HAND) in the aged is a clinical diagnosis but is associated, in measure, with atrophy of the nigrostriatum and frontostriatal circuits and early signs of beta-amyloidosis, microtubule-associated tau aggregation, and alpha synuclein inclusions. Such findings are seen in Alzheimer's and Parkinson's diseases (AD and PD). For PD and HAND, in particular, common anatomical, immunologic and neurochemical axes exist within the nigrostriatum. In recent years our laboratories uncovered a bridge between both diseases through linked adaptive immune activities serving to halt neuronal loss seen in models of HAND, PD, AD and amyotrophic lateral sclerosis. These findings suggest that multicellular regulatory responses exist for both virus and brain-specific proteins. To test this notion we will profile, the principal target cell(s) for viru in the nervous system, the mononuclear phagocyte in a laboratory setting reflective of PD and HAND. This will be done through proteomic, bioinformatic and functional immune tests following chronic HIV and/or misfolded and aggregated nitrated alpha synuclein (N-a-syn) exposures. Based on the cellular profiles seen we will investigate neural and immune responses observed in brains of HIV-1 infected humanized mice exposed to 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or to N-a-syn. Here we will assess how neuronal and glial responses affected by each pathobiologic event alone and together in disease-effected specific brain subregions and performed in the setting of combination antiretroviral therapy (cART). Neuropathologic evaluations will be linked to T cell subsets and viral load tests to provide correlation between neurodegeneration with immune profiling. Coordinate magnetic resonance imaging and behavioral testing for screening of brain impairments and stable isotope labeling of amino acids in mammals for mechanistic study will anchor protein chemistry, histology, cognition and immunology to neurodegenerative processes. To substantiate the links of adaptive immunity to neurodegeneration we will perform immune-based therapeutic interventions to halt neurodegeneration. In this manner the mechanism of and the means to correct such functional neuronal deficit(s) will be sought. These studies will uncover the role of chronic HIV infection on the onset of progression of parallel neurodegenerative processes and means to intervene. Such studies tackle changing patterns of neuroAIDS in the era of cART with an eye towards changes in behavioral impairments. An interdisciplinary team of investigators with a strong track record of working together successfully was assembled for these studies.

Public Health Relevance

Both human immunodeficiency virus (HIV) infection of the nervous system and Parkinson's disease (PD) (driven by misfolded, nitrated and aggregated alpha synuclein) lead to robust immune responses that drive neuronal injury and cognitive impairments. How the two influence one another is not known;but as HIV- infected people age, the influences of the two on one another will be more significant. To this end we will investigate, in laboratory and animal models of HIV and PD, the means to better understand how the two diseases affect one another with an eye towards bench to bedside translation.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01NS034239-20
Application #
8679011
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Wong, May
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Araínga, Mariluz; Su, Hang; Poluektova, Larisa Y et al. (2016) HIV-1 cellular and tissue replication patterns in infected humanized mice. Sci Rep 6:23513
Olson, Katherine E; Gendelman, Howard E (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Curr Opin Pharmacol 26:87-95
Olson, Katherine E; Bade, Aditya N; Schutt, Charles R et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics 13:635-46
Li, Weizhe; Tong, Hsin-I; Gorantla, Santhi et al. (2016) Neuropharmacologic Approaches to Restore the Brain's Microenvironment. J Neuroimmune Pharmacol 11:484-94
Singh, Dhirender; McMillan, JoEllyn; Hilaire, James et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) 11:1913-27
Sajja, Balasrinivasa R; Bade, Aditya N; Zhou, Biyun et al. (2016) Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγc(null) Mouse Brain Atlas. J Neuroimmune Pharmacol 11:133-41
Bade, Aditya N; Gorantla, Santhi; Dash, Prasanta K et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Mol Neurobiol 53:3286-97
Wiesman, Alex I; Heinrichs-Graham, Elizabeth; McDermott, Timothy J et al. (2016) Quiet connections: Reduced fronto-temporal connectivity in nondemented Parkinson's Disease during working memory encoding. Hum Brain Mapp 37:3224-35
Zhang, Gang; Guo, Dongwei; Dash, Prasanta K et al. (2016) The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12:109-22
Dong, Weiguo; Embury, Christine M; Lu, Yaman et al. (2016) The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. J Neuroinflammation 13:184

Showing the most recent 10 out of 165 publications